Pyronaridine-Artesunate (Pyramax) for Treatment of Artemisinin- and Piperaquine-Resistant Plasmodium falciparum in the Central Highlands of Vietnam

Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso

(2021) Yves Daniel Compaoré et al.   MALARIA JOURNAL

Efficacy and safety of pyronaridine-artesunate plus single-dose primaquine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Cambodia

(2019) Rithea Leang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam

(2019) Nguyen Chinh Phong et al.   MALARIA JOURNAL

Pyronaridine-artesunate plus single-dose primaquine efficacy and safety for the treatment of malaria in western Cambodia

(2019) Rithea Leang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pyronaridine-artesunate efficacy and safety in uncomplicated Plasmodium falciparum malaria in areas of artemisinin-resistant falciparum in Viet Nam (2017–2018)

(2019) Phuc Bui Quang et al.   CLINICAL INFECTIOUS DISEASES

Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study

(2019) William L Hamilton et al.   LANCET INFECTIOUS DISEASES

Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study

(2019) Rob W van der Pluijm et al.   LANCET INFECTIOUS DISEASES

Comparison of the Pharmacokinetics and Ex Vivo Antimalarial Activities of Artesunate–Amodiaquine and Artemisinin–Piperaquine in Healthy Volunteers for Preselection Malaria Therapy

(2018) Nguyen Ngoc Quang et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial

(2018) Issaka Sagara et al.   LANCET

Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine

(2018) Leila S. Ross et al.   Nature Communications

Genetic markers associated with dihydroartemisinin–piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype–phenotype association study

(2017) Roberto Amato et al.   LANCET INFECTIOUS DISEASES

A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype–genotype association study

(2017) Benoit Witkowski et al.   LANCET INFECTIOUS DISEASES

Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin–piperaquine in the south of Vietnam

(2017) Ngo Viet Thanh et al.   MALARIA JOURNAL

Efficacy and Safety of Pyronaridine-Artesunate for Treatment of Uncomplicated Plasmodium falciparum Malaria in Western Cambodia

(2016) Rithea Leang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients

(2015) Amal Ayyoub et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations

(2015) Valentine Duru et al.   BMC Medicine

Benefits of a Pharmacology Antimalarial Reference Standard and Proficiency Testing Program Provided by the Worldwide Antimalarial Resistance Network (WWARN)

(2014) Chris Lourens et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetic Interactions between Primaquine and Pyronaridine-Artesunate in Healthy Adult Thai Subjects

(2014) Podjanee Jittamala et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies

(2013) Benoit Witkowski et al.   LANCET INFECTIOUS DISEASES

Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials

(2013) Stephan Duparc et al.   MALARIA JOURNAL

A molecular marker of artemisinin-resistant Plasmodium falciparum malaria

(2013) Frédéric Ariey et al.   NATURE

Pyronaridine–Artesunate versus Mefloquine plus Artesunate for Malaria

(2012) Ronnatrai Rueangweerayut et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics andEx VivoAntimalarial Activity of Artesunate-Azithromycin in Healthy Volunteers

(2011) Nguyen Trong Chinh et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration

(2011) Carrie A Morris et al.   MALARIA JOURNAL

Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator

(2011) Jennifer A Flegg et al.   MALARIA JOURNAL

Role of pfmdr1 Amplification and Expression in Induction of Resistance to Artemisinin Derivatives in Plasmodium falciparum

(2010) M. Chavchich et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vivo Parasitological Measures of Artemisinin Susceptibility

(2010) Kasia Stepniewska et al.   JOURNAL OF INFECTIOUS DISEASES

Absence of time-dependent artesunate pharmacokinetics in healthy subjects during 5-day oral administration

(2008) L. T. Diem Thuy et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY